MedTrace Logo

Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery

NCT02314871 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-03-13

No results posted yet for this study

Summary

The aim of this study is to compare the effects of three types of perioperative analgesia on the number of circulating cancer cells (representing minimal residual disease) following radical colon cancer surgery. Patients will be randomized into one of three groups. The intervention group will receive combined regional and general anesthesia during surgery and postoperative epidural analgesia. The two control groups will receive balanced general anesthesia and either morphine-based or piritramide-based postoperative analgesia. We hypothesize that epidural analgesia will be favorable to both piritramide-based and morphine-based analgesia and that piritramide-based analgesia will be favorable to morphine-based analgesia with regard to the number of circulating cancer cells and its development in the early postoperative period.

Conditions

Interventions

OTHER

Epidural analgesia

see Arm/group description

DRUG

Piritramide

see Arm/group description

DRUG

Morphine

see Arm/group description

Sponsors & Collaborators

  • Brno University Hospital

    collaborator OTHER

  • Tomas Bata Hospital, Czech Republic

    collaborator OTHER

  • The Institute of Molecular and Translational Medicine, Czech Republic

    lead OTHER

Principal Investigators

  • Emil Berta, MD PhD · The Institute of Molecular and Translational Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02314871 on ClinicalTrials.gov